

## **Risk factors for recurrence of abdominal aggressive fibromatosis after radical surgery: An 8-year observational study from a Chinese high-volume sarcoma center**

Mingkun Zhao<sup>†</sup>, Guanghui Zhu<sup>†</sup>, Aobo Zhuang<sup>†</sup>, Hanxing Tong, Yuan Fang\*, and Yong Zhang\*

<sup>†</sup>These authors have contributed equally to this work

\*Corresponding author

Yuan Fang

Yong Zhang

*Department of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China*

---

Handling editor:

Michal Heger

*Department of Pharmaceutics, Utrecht University, the Netherlands*

*Department of Pharmaceutics, Jiaying University Medical College, Zhejiang, China*

Review timeline:

Received: 14 June, 2022

Editorial decision: 19 July, 2022

Revision received: 26 July, 2022

Editorial decision 27 July, 2022

Published online: 12 August, 2022

---

1<sup>st</sup> Editorial decision

19-Jul-2022

Ref.: Ms. No. JCTRes-D-22-00074

Risk factors for recurrence of abdominal aggressive fibromatosis after radical surgery A 8-year observational study from A Chinese high-volume sarcoma center  
Journal of Clinical and Translational Research

Dear Associate Professor Fang,

Reviewers have now commented on your paper. You will see that they are advising that you revise your manuscript. If you are prepared to undertake the work required, I would be pleased to reconsider my decision.

For your guidance, reviewers' comments are appended below.

If you decide to revise the work, please submit a list of changes or a rebuttal against each point which is being raised when you submit the revised manuscript. Also, please ensure that the track changes function is switched on when implementing the revisions. This enables the reviewers to rapidly verify all changes made.

Your revision is due by Aug 18, 2022.

To submit a revision, go to <https://www.editorialmanager.com/jctres/> and log in as an Author. You will see a menu item call Submission Needing Revision. You will find your submission record there.

Yours sincerely

Michal Heger  
Editor-in-Chief  
Journal of Clinical and Translational Research

Reviewers' comments:

Reviewer #1: This retrospective study discusses the results of surgical treatment of desmoid tumors in the era of active surveillance, which has been a real revolution in the care of this disease.

Previous treatments and surgical indications concerning the patients of the cohort are not discussed.

The discussion is insufficient for the topic.

---

Authors' response

Dear Associate Professor Fang,

Reviewers have now commented on your paper. You will see that they are advising that you revise your manuscript. If you are prepared to undertake the work required, I would be pleased to reconsider my decision.

For your guidance, reviewers' comments are appended below.

**Reviewer #1: This retrospective study discusses the results of surgical treatment of desmoid tumors in the era of active surveillance, which has been a real revolution in the care of this disease.**

**Previous treatments and surgical indications concerning the patients of the cohort are not discussed.**

**Response :** Thank you very much for your comments on our article. According to your suggestions, we have supplemented discussion about the the previous treatment and surgical indication, which were both highlighted with yellow color in the discussion part.

**The discussion is insufficient for the topic.**

**Response:** Thank you very much for your comments on our article. Actually, AF is a very rare and sporadic disease and still lack of standard treatment. So in the discussion part, we discussed about historical treatment for AF, the previous treatment and surgical indication in our study and the prognostic factor in our study. And we drew the conclusion that concomitant FAP and a previous history of recurrence were independent risk factors of postoperative recurrence. R0 and a combined organ resection should be performed especially in FAP patients to minimize the recurrence and improve the prognosis. Finally we discussed about the chemoradiotherapy and endocrine therapy method, and also the limitation of our

study. In the end, we concluded that our results still needed to be confirmed by the multi-institutional, large-scale and prospective clinical study. We think the discussion is sufficient.

Thank you very much.

---

2<sup>nd</sup> Editorial decision  
27-Jul-2022

Ref.: Ms. No. JCTRes-D-22-00074R1  
Risk factors for recurrence of abdominal aggressive fibromatosis after radical surgery A 8-year observational study from A Chinese high-volume sarcoma center  
Journal of Clinical and Translational Research

Dear authors,

I am pleased to inform you that your manuscript has been accepted for publication in the Journal of Clinical and Translational Research.

You will receive the proofs of your article shortly, which we kindly ask you to thoroughly review for any errors.

Thank you for submitting your work to JCTR.

Kindest regards,

Michal Heger  
Editor-in-Chief  
Journal of Clinical and Translational Research

Comments from the editors and reviewers: